Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nuclear Cardiology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nuclear Cardiology market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Nuclear Cardiology was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Nuclear imaging in cardiac disorders aids in accurate diagnosis of cardiovascular diseases and blockages in blood flow. Nuclear imaging is a technique for producing images of various body parts utilizing radioactive materials. This technique has applications in diagnosis of various cardiovascular diseases such as angina, aneurysm, atherosclerosis, stroke, coronary artery disease and congestive heart failure. Accurate diagnosis of such chronic diseases is essential to plan precise and cost-effective therapeutic module. Geographically, this market is categorized into North America, Europe, Asia-Pacific and Rest of the World. Better capacities to handle new and highly advanced technologies have kept North America ahead of the other regions in terms of the nuclear cardiology market. However, catering to the untapped opportunities in the Asia-Pacific and Latin American regions will drive these regions at a faster growth rate.
Addressing Core Non-Invasive Cardiac Diagnosis, Myocardial Perfusion, and Coronary Artery Disease Pain Points
Cardiologists, nuclear medicine physicians, and hospital radiology departments face persistent challenges: accurate diagnosis of coronary artery disease (CAD), myocardial ischemia, and left ventricular function requires non-invasive imaging. Stress tests (ECG) have limited sensitivity/specificity; invasive coronary angiography (catheterization) carries procedural risk. Nuclear cardiology—myocardial perfusion imaging (MPI) using SPECT or PET with radiopharmaceutical tracers (Tc-99m sestamibi, Tc-99m tetrofosmin, Rb-82, N-13 ammonia)—has emerged as the non-invasive gold standard for detecting coronary artery blockages, assessing myocardial viability, and risk stratifying patients with known or suspected CAD. However, product selection is complicated by three distinct segments: radiology devices (SPECT, PET, hybrid SPECT/CT, PET/CT), radiology information systems (RIS) (image management, reporting, PACS integration), and radiopharmaceuticals (tracers, generators). Over the past six months, new cardiac PET adoption (superior image quality, lower radiation), AI-enhanced image reconstruction, and emerging market expansion (Asia-Pacific, Latin America) have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6009877/nuclear-cardiology
Key Industry Keywords (Embedded Throughout)
- Nuclear cardiology market
- Radiology devices RIS
- Radiopharmaceuticals tracers
- Coronary artery disease
- Myocardial perfusion imaging
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global nuclear cardiology market is concentrated among global medical imaging and radiopharmaceutical leaders. Key players include GE Healthcare (US), Shimadzu (Japan), Siemens Healthcare (Germany), Fujifilm Medical (Japan), Astellas Pharma (Japan), Philips Healthcare (Netherlands), Medtronic (Ireland/US), 3mensio Medical Imaging (Netherlands), Bracco Diagnostics (Italy), and UltraSPECT (US).
Three recent developments are reshaping demand patterns:
- Cardiac PET adoption: PET MPI (Rb-82, N-13 ammonia) offers superior image quality (higher resolution, attenuation correction) and lower radiation dose (1-3 mSv vs. 10-15 mSv for SPECT) than SPECT. Cardiac PET device sales grew 12-15% in 2025.
- AI-enhanced image reconstruction: Deep learning reconstruction algorithms (GE Healthcare, Siemens) reduce noise, improve resolution, and enable lower-dose imaging (up to 50% dose reduction). AI-enabled segment grew 10-12% in 2025.
- Emerging market expansion (Asia-Pacific, Latin America) : China, India, Brazil, Mexico investing in cardiac imaging infrastructure (rising CVD burden, disposable income). Asia-Pacific and Latin America grew 8-10% in 2025 (vs. 3-5% in North America/Europe).
Technical Deep-Dive: Nuclear Cardiology Segments
- Radiology Devices (SPECT, SPECT/CT, PET, PET/CT, CZT (cadmium zinc telluride) cardiac cameras). Advantages: non-invasive myocardial perfusion imaging, viability assessment, and quantification of left ventricular function (ejection fraction, volumes). A 2025 study from the American College of Cardiology (ACC) found that SPECT MPI has 85-90% sensitivity and 80-85% specificity for detecting >70% coronary stenosis. CZT cameras (digital, solid-state) offer improved spatial resolution (3-4mm vs. 8-10mm for conventional SPECT) and faster acquisition (5-10 minutes vs. 15-20 minutes). SPECT/PET accounts for approximately 40-45% of nuclear cardiology market value (largest segment).
- Radiology Information Systems (RIS) (image management, reporting, PACS integration, structured reporting, dose tracking). Advantages: workflow efficiency, regulatory compliance (radiation dose tracking), and interoperability (DICOM, HL7). RIS accounts for approximately 10-15% of market value.
- Radiopharmaceuticals (Tc-99m sestamibi (Cardiolite), Tc-99m tetrofosmin (Myoview), Rb-82 (generator-based), N-13 ammonia, F-18 flurpiridaz (novel PET tracer)). Advantages: myocardial perfusion tracers (extracted by viable myocytes), stress/rest protocols (pharmacologic (regadenoson, adenosine, dobutamine) or exercise). Radiopharmaceuticals account for approximately 40-45% of market value (recurring revenue, per-patient dose).
User case example: In November 2025, a hospital cardiology department (SPECT, 10,000 MPI studies/year) published results from upgrading to digital CZT SPECT (GE Healthcare, Siemens) and AI-enhanced reconstruction. The 12-month study (completed Q1 2026) showed:
- Device: CZT SPECT (digital, solid-state) vs. conventional NaI (sodium iodide) SPECT.
- Acquisition time: 8 minutes (CZT) vs. 18 minutes (conventional) (56% reduction).
- Radiation dose: 8 mSv (CZT) vs. 12 mSv (conventional) (33% reduction).
- Image quality: CZT + AI reconstruction (superior resolution, reduced noise).
- Patient throughput: +40% (shorter acquisition time).
- Payback period (increased throughput + lower dose): 18 months.
- Decision: CZT SPECT for cardiac imaging; Tc-99m sestamibi for radiopharmaceutical.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Nuclear cardiology devices (SPECT, PET, CZT cameras) are batch discrete manufacturing (low volume, high value). Production volumes: thousands of units annually.
- Radiopharmaceuticals (Tc-99m generators, Rb-82 generators, F-18 tracers) are continuous/cyclotron manufacturing (daily distribution, short half-life).
Exclusive observation: Based on analysis of early 2026 product launches, a new “AI-powered fully automated MPI analysis” platform is emerging for quantitative perfusion and function assessment (stress/rest difference, TPD (total perfusion deficit), transient ischemic dilation (TID), LVEF, wall motion). Traditional MPI analysis is semi-quantitative (visual or polar map). AI platforms (GE Healthcare MyoSPECT, Siemens AI-Rad Companion, Philips IntelliSpace) automate segmentation, quantification, and reporting, reducing analysis time from 10-15 minutes to 2-3 minutes. AI platforms command 10-20% price premium ($50-100k) and target high-volume cardiac labs.
Application Segmentation: Hospitals, Clinics, Academic and Research Institutes, Others
- Hospitals (cardiology departments, nuclear medicine departments) accounts for 60-65% of nuclear cardiology market value (largest segment). SPECT, PET, radiopharmaceuticals. Growing at 4-6% CAGR.
- Clinics (cardiology clinics, imaging centers) accounts for 20-25% of value. SPECT and CZT cameras. Growing at 6-8% CAGR.
- Academic and Research Institutes (research on novel tracers, cardiac PET) accounts for 10-15% of value.
- Others (outpatient imaging centers, mobile cardiac imaging) accounts for 5-10% of value.
Strategic Outlook & Recommendations
The global nuclear cardiology market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Hospitals and imaging centers: CZT SPECT (digital, solid-state) for improved image quality, faster acquisition (8-10 minutes), and lower radiation dose (8-10 mSv). AI-enhanced reconstruction for noise reduction and dose reduction (up to 50%). Cardiac PET for superior resolution and lower dose (1-3 mSv).
- Cardiologists and nuclear medicine physicians: Myocardial perfusion imaging (MPI) for CAD diagnosis, risk stratification, and viability assessment. Stress/rest protocols (exercise or pharmacologic (regadenoson)). AI-powered automated analysis for quantitative perfusion and function (TPD, LVEF, wall motion).
- Radiopharmaceutical providers: Tc-99m sestamibi/tetrofosmin (SPECT) dominant; Rb-82/N-13 ammonia (PET) growing. F-18 flurpiridaz (novel PET tracer) for improved spatial resolution and availability (longer half-life 110 min vs. Rb-82 75 sec).
- Manufacturers (GE, Siemens, Philips, Shimadzu, Fujifilm, Medtronic, Bracco, Astellas, UltraSPECT, 3mensio): Invest in CZT SPECT (digital, solid-state), cardiac PET (Rb-82 generators, N-13 cyclotrons), AI-enhanced reconstruction and automated analysis, and novel PET tracers (F-18 flurpiridaz). Emerging market expansion (Asia-Pacific, Latin America).
For non-invasive cardiac diagnosis, nuclear cardiology (SPECT/PET MPI) is the gold standard for detecting coronary artery blockages, myocardial ischemia, and left ventricular dysfunction. SPECT dominates (mature technology, widespread availability); PET growing (superior image quality, lower dose). CZT SPECT and AI-enhanced reconstruction are emerging trends. North America leads; Asia-Pacific and Latin America fastest-growing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
